Literature DB >> 29103701

Are vaccine strain, type or administration protocol risk factors for canine parvovirus vaccine failure?

K D Altman1, M Kelman2, M P Ward3.   

Abstract

Canine parvovirus (CPV) is a highly contagious and worldwide cause of serious and often fatal disease in dogs, despite the widespread availability of vaccines. Which vaccine-related factors are associated with vaccination failure is largely unknown, and there are no reports from Australia. In this study - the first national population-level CPV study of its kind ever conducted - we analysed data on 594 cases of apparent CPV vaccination failure reported from an Australian national surveillance system to determine whether vaccine strain, type or administration protocol are risk factors for vaccination failures. The strain of CPV used in vaccine manufacture was not significantly associated with vaccination failure in clinical practice. The vaccine type (killed versus attenuated vaccine) for puppies diagnosed with CPV was associated with a lower mean age at time of vaccination (P=0.0495). The age at administration of the last CPV vaccination a puppy received prior to presenting with disease was a significant (P=0.0334) risk factor for vaccination failure, irrespective of whether the vaccine was marketed for a 10-week or 12-week or greater vaccination finish protocol. There was also a strong negative correlation between age at last vaccination prior to disease and vaccination failure (P<0.0001): the later a puppy received this last vaccination, the lower the risk of vaccination failure. This supports the hypothesis that the use of final vaccination in puppies at less than 16 weeks of age predisposes to vaccination failure and warrants a final age for vaccination recommendation to be at least 16 weeks for all canine parvovirus vaccines, especially in outbreak situations. The large number of cases identified in this study confirms that CPV vaccination failure is occurring in Australia. Veterinarians should consider CPV as a differential diagnosis in cases with appropriate clinical presentation, regardless of the reported vaccination status of the dog.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Australia; CPV strain; Canine parvovirus; Risk factors; Vaccination failure

Mesh:

Substances:

Year:  2017        PMID: 29103701     DOI: 10.1016/j.vetmic.2017.08.019

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  9 in total

1.  Canine parvovirus type 2c in Vietnam continues to produce distinct descendants with new mutations restricted to Vietnamese variants.

Authors:  Huong Thi Thanh Doan; Xuyen Thi Kim Le; Roan Thi Do; Khue Thi Nguyen; Thanh Hoa Le
Journal:  Arch Virol       Date:  2021-04-16       Impact factor: 2.574

2.  Exclusive circulation of canine parvovirus type 2c in the Guadalajara metropolitan area in western Mexico: a five-year study.

Authors:  César Pedroza-Roldán; Martín Alejandro Hernández-Almaraz; Darwin Elizondo-Quiroga; Abel Gutierrez-Ortega; Carlos Maximiliano Acosta-Monroy; Claudia Charles-Niño; Mauricio Realpe-Quintero; Sandra Del Carmen Robles-Gil
Journal:  Arch Virol       Date:  2022-07-06       Impact factor: 2.685

3.  Molecular Investigation of Recent Canine Parvovirus-2 (CPV-2) in Italy Revealed Distinct Clustering.

Authors:  Marilena Carrino; Luca Tassoni; Mery Campalto; Lara Cavicchio; Monica Mion; Michela Corrò; Alda Natale; Maria Serena Beato
Journal:  Viruses       Date:  2022-04-28       Impact factor: 5.818

4.  First report of canine parvovirus molecular detection in Bangladesh.

Authors:  F M Yasir Hasib; Sharmin Akter; Sharmin Chowdhury
Journal:  Vet World       Date:  2021-04-29

5.  Socioeconomic, geographic and climatic risk factors for canine parvovirus infection and euthanasia in Australia.

Authors:  Mark Kelman; Vanessa R Barrs; Jacqueline M Norris; Michael P Ward
Journal:  Prev Vet Med       Date:  2019-11-10       Impact factor: 2.670

6.  The relationship between reported domestic canine parvovirus cases and wild canid distribution.

Authors:  Alicia Van Arkel; Mark Kelman; Peter West; Michael P Ward
Journal:  Heliyon       Date:  2019-09-23

7.  The first evaluation of the effectiveness of canine vaccination schedule by two commercial vaccines in Iran.

Authors:  F Shams; H Pourtaghi; Z Abdolmaleki
Journal:  BMC Vet Res       Date:  2022-03-29       Impact factor: 2.741

Review 8.  Canine parvovirus vaccination and immunisation failures: Are we far from disease eradication?

Authors:  N Decaro; C Buonavoglia; V R Barrs
Journal:  Vet Microbiol       Date:  2020-06-15       Impact factor: 3.293

9.  Diagnostic Challenges in Canine Parvovirus 2c in Vaccine Failure Cases.

Authors:  Hiu Ying Esther Yip; Anne Peaston; Lucy Woolford; Shiow Jing Khuu; Georgia Wallace; Rohan Suresh Kumar; Kandarp Patel; Ania Ahani Azari; Malihe Akbarzadeh; Maryam Sharifian; Reza Amanollahi; Razi Jafari Jozani; Aliakbar Khabiri; Farhid Hemmatzadeh
Journal:  Viruses       Date:  2020-09-03       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.